Insulet Corp (Insulet) is a medical device company that develops, manufactures and distributes insulin management systems for diabetic patients. Its insulin management system, OmniPod, is a continuous insulin delivery system for insulin dependent diabetics. The OmniPod system consists of a disposable self- adhesive tubeless insulin infusion device, and a handheld wireless device, Personal Diabetes Manager. The company also works in partnership with various biotechnology and pharmaceutical companies that use the customized form of its OmniPod system to deliver drugs at specified intervals at predetermined doses. The company markets its products directly and through distributors in the US, Canada, Israel, China, and the UK, among others. Insulet is headquartered in Acton, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Insulet Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Insulet Corp Company Overview
- Insulet Corp Company Snapshot
- Insulet Corp Pipeline Products and Ongoing Clinical Trials Overview
- Insulet Corp - Pipeline Analysis Overview
- Business Description
- Insulet Corp - Key Facts
- Insulet Corp - Major Products and Services
- Insulet Corp Pipeline Products by Development Stage
- Insulet Corp Ongoing Clinical Trials by Trial Status
- Insulet Corp Pipeline Products Overview
- Omnipod 5
- Omnipod 5 Product Overview
- Omnipod 5 Clinical Trial
- Omnipod DASH Insulin Management System
- Omnipod DASH Insulin Management System Product Overview
- Omnipod GO
- Omnipod GO Product Overview
- Omnipod U-200 Insulin Management System
- Omnipod U-200 Insulin Management System Product Overview
- Omnipod U-500 Insulin Management System
- Omnipod U-500 Insulin Management System Product Overview
- Insulet Corp - Key Competitors
- Insulet Corp - Key Employees
- Insulet Corp - Key Employee Biographies
- Insulet Corp - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Insulet Corp, Recent Developments
- Feb 24, 2023: Insulet Reports Full Year 2022 Revenue Increase of 19% and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year
- Jan 12, 2023: Insulet to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
- Sep 22, 2022: Insulet to Announce Third Quarter 2022 Financial Results on November 3, 2022
- Jun 02, 2022: Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference
- May 05, 2022: Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year
- May 05, 2022: Insulet Announces CEO Transition
- Apr 07, 2022: Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022
- Feb 16, 2022: Insulet to Present at Upcoming Investor Conferences
- Feb 07, 2022: Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine
- Jan 12, 2022: Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Insulet Corp Pipeline Products and Ongoing Clinical Trials Overview
- Insulet Corp Pipeline Products by Equipment Type
- Insulet Corp Pipeline Products by Indication
- Insulet Corp Ongoing Clinical Trials by Trial Status
- Insulet Corp, Key Facts
- Insulet Corp, Major Products and Services
- Insulet Corp Number of Pipeline Products by Development Stage
- Insulet Corp Pipeline Products Summary by Development Stage
- Insulet Corp Ongoing Clinical Trials by Trial Status
- Insulet Corp Ongoing Clinical Trials Summary
- Omnipod 5 - Product Status
- Omnipod 5 - Product Description
- Omnipod 5 - Efficacy and Safety of the Omnipod 5 System Compared to Pump Therapy in the Treatment of Type 1 Diabetes: A Randomized, Parallel-Group Clinical Trial
- Omnipod 5 - Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients with Type 1 Diabetes
- Omnipod 5 - Safety and Efficacy of the Omnipod 5 Automated Insulin Delivery System in Adults with Type 2 Diabetes
- Omnipod DASH Insulin Management System - Product Status
- Omnipod DASH Insulin Management System - Product Description
- Omnipod GO - Product Status
- Omnipod GO - Product Description
- Omnipod U-200 Insulin Management System - Product Status
- Omnipod U-200 Insulin Management System - Product Description
- Omnipod U-500 Insulin Management System - Product Status
- Omnipod U-500 Insulin Management System - Product Description
- Insulet Corp, Key Employees
- Insulet Corp, Key Employee Biographies
- Insulet Corp, Other Locations
- Insulet Corp, Subsidiaries
- Glossary
- Insulet Corp Pipeline Products by Equipment Type
- Insulet Corp Pipeline Products by Development Stage
- Insulet Corp Ongoing Clinical Trials by Trial Status
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- DexCom Inc
- West Pharmaceutical Services Inc
- Tandem Diabetes Care Inc
- Valeritas Inc
- Medtronic MiniMed Inc
